Targeted Agents and Immunotherapy in Pretreated CRC and HCC
Expert Review
Expert Review

Targeted Agents and Immunotherapy in Pretreated CRC and HCC

Current Perspectives

Not a member of My prIME? Join now for instant access.

Update your treatment management options in pretreated colorectal cancer (CRC) and hepatocellular carcinoma (HCC) through thought-leader discussion with an associated slide deck, featuring exciting new data from the 2017 Annual Gastrointestinal Cancer Meeting in Barcelona and the 2017 Annual Oncology Meeting in Chicago.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jul 5, 2017

Expiration Date

Jul 5, 2018

Featured Experts

  • Jordi Bruix, MD, PhDUniversity of Barcelona
    Barcelona, Spain
  • Michel Ducreux, MD, PhDGustave Roussy
    Villejuif, France

2017 Annual Gastrointestinal Cancer Meeting in Barcelona

Abstract O-009: Updated Overall Survival (OS) Analysis From the International, Phase 3, Randomized, Placebo-Controlled RESORCE Trial of Regorafenib for Patients With Hepatocellular Carcinoma (HCC) Who Progressed on Sorafenib Treatment
Abstract PD-025: Real-World Dosing of Regorafenib in Metastatic Colorectal Cancer (mCRC): Interim Analysis From the Prospective, Observational CORRELATE Study

2017 Annual Oncology Meeting in Chicago

Abstract #3531: Combination of Nivolumab (nivo) + Ipilimumab (Ipi) In The Treatment Of Patients (Pts) With Deficient DNA Mismatch Repair (dMMR)/High Microsatellite Instability (MSI-H) Metastatic Colorectal Cancer (mCRC): CheckMate 142 Study
Abstract #4013: Nivolumab (nivo) in Sorafenib (sor)-Naive and -Experienced Pts With Advanced Hepatocellular Carcinoma (HCC): CheckMate 040 Study

2017 Annual Oncology Meeting in Chicago

Abstract 519: Nivolumab In Patients with DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142

This activity is intended for medical oncologists, gastroenterologists, radiation and surgical oncologists, and other healthcare professionals involved in the management of patients with CRC and/or HCC.

After successful completion of this educational activity, participants should be able to:

  • Evaluate emerging clinical trial data in pretreated CRC and HCC, including studies focused on the safety and efficacy of novel targeted therapies
  • Select patients who may benefit from emerging therapies in pretreated CRC and HCC

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.